On January 28, 2025 Cordance Medical, a pioneer in non-invasive medical technologies for brain disease treatment, and EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, reported initial positive results indicating more than a doubling (+127-145%) of the uptake of a radiopharmaceutical in brain tumors of mice inoculated with glioblastoma cancer cells, one of the most aggressive and hard-to-treat brain cancers (Press release, Cordance Medical, JAN 28, 2025, View Source [SID1234649914]). The increased uptake resulted from combining Exact Therapeutics’ proprietary Acoustic Cluster Therapy (ACT) with a device designed by Cordance Medical to deliver ultrasound energy non-invasively into the brain. The studies were performed at The Arctic University of Norway and University Hospital North-Norway in Tromsø by Dr. Mathias Kranz.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The combination of ACT and the device can be used in a wide range of brain diseases to potentially access large regions of the brain. The combination can stimulate bioeffects including increasing the uptake of therapeutic agents and temporarily making the blood-brain barrier more permeable in these regions. The combination of ACT and the device may be utilized for both diagnostic and targeted therapeutic brain applications. Further experiments are ongoing to expand the early data, and the results will be submitted for publication in scientific journals.
"The combination of the Cordance technology and the ACT microcluster technology from Exact Therapeutics provides exciting possibilities for accessing and opening larger volumes in the brain without necessarily increasing the focused ultrasound procedure time or the total amount of ultrasound energy," said Dr. Bhaskar Ramamurthy Cofounder and CEO of Cordance Medical.
"These positive results in glioblastoma provide additional early evidence of the versatility of the noninvasive ACT microcluster technology in cancer therapy. Oncology is the key focus for Exact Therapeutics, spearheaded by our ongoing Phase 2 trial in locally advanced pancreatic cancer, which received IND clearance at the end of 2024," said Dr. Per Walday, CEO of Exact Therapeutics.